Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06 2024 - 4:01PM
Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024,
the Compensation Committee of Chimerix’s Board of Directors granted
inducement awards to three new employees of non-statutory stock
options to purchase up to a total of 385,000 shares of Chimerix’s
common stock. The Compensation Committee of Chimerix’s Board of
Directors approved the awards as an inducement material to the new
employees’ employment in accordance with Nasdaq Listing rule
5635(c)(4).
The stock options have an exercise price per share equal to
Chimerix’s closing trading price as of the grant date. The stock
options have a 10-year term and will vest over four years, with
one-fourth vesting on the one-year anniversary of the date of hire
and the remaining three-fourths vesting over the following three
years in equal monthly installments. The stock options are subject
to the terms of Chimerix’s 2024 Equity Incentive Plan but were
granted outside of the 2024 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, dordaviprone (ONC201), is in
development for H3 K27M-mutant glioma. The Company is
conducting Phase 1 dose escalation studies of ONC206 to evaluate
safety and PK data.
CONTACTS: Will
O’ConnorStern Investor
Relations212-362-1200ir@chimerix.comwill@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Dec 2023 to Dec 2024